

## HR 6577

### PRICED Act

**Congress:** 115 (2017–2019, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Jul 26, 2018

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Jul 27, 2018)

**Official Text:** <https://www.congress.gov/bill/115th-congress/house-bill/6577>

### Sponsor

**Name:** Rep. Schakowsky, Janice D. [D-IL-9]

**Party:** Democratic • **State:** IL • **Chamber:** House

### Cosponsors

*No cosponsors are listed for this bill.*

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jul 27, 2018

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

*No related bills are listed.*

### Summary (as of Jul 26, 2018)

#### Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.

This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

## Actions Timeline

---

- **Jul 27, 2018:** Referred to the Subcommittee on Health.
- **Jul 26, 2018:** Introduced in House
- **Jul 26, 2018:** Referred to the House Committee on Energy and Commerce.